NewsEarningsAcutaas Chemicals Reports Robust Q2 FY26 Results with 24% Revenue Growth and Margin ExpansionAcutaas Chemicals Reports Robust Q2 FY26 Results with 24% Revenue Growth and Margin Expansion
Acutaas Chemicals Limited reported robust Q2 FY26 results with revenue up 24.10% to INR 306.20 crores. EBITDA doubled to INR 95.30 crores, and PAT increased 91.30% to INR 71.90 crores. The Advanced Pharmaceutical Intermediates segment grew 27.10%, while Specialty Chemicals rose 7.30%. H1 FY26 saw total revenue increase 21.30% to INR 513.40 crores. The company plans a INR 180 crore capex for its Electrolyte Additives Project and INR 30 crores for a Pilot Plant. Acutaas revised its FY26 EBITDA margin guidance to 28-30% and maintains a 25% revenue growth target.
*this image is generated using AI for illustrative purposes only.
Acutaas Chemicals Limited , a leading player in the specialty chemicals and pharmaceutical intermediates sector, has reported strong financial results for the second quarter of fiscal year 2026, showcasing significant growth and margin expansion.
Key Financial Highlights
| Metric | Q2 FY26 | Y-o-Y Growth |
|---|---|---|
| Revenue | INR 306.20 crores | 24.10% |
| EBITDA | INR 95.30 crores | ~100.00% |
| EBITDA Margin | 31.10% | 1,130 bps |
| PAT | INR 71.90 crores | 91.30% |
| PAT Margin | 23.50% | 824 bps |
Segment-wise Performance
Advanced Pharmaceutical Intermediates
- Revenue: INR 262.60 crores, up 27.10% year-on-year
- Growth primarily driven by expansion in CDMO business
Specialty Chemicals
- Revenue: INR 43.60 crores, up 7.30% year-on-year
H1 FY26 Performance
- Total revenue: INR 513.40 crores, up 21.30% year-on-year
- EBITDA: INR 146.20 crores, up 86.40% year-on-year
- PAT: INR 115.90 crores, more than doubled compared to H1 FY25
Strategic Developments
Electrolyte Additives Project:
- Capex of INR 180 crores planned for FY26
- Expected completion by Q4 FY26
- Full commercial production anticipated in FY27
Pilot Plant Capex:
- INR 30 crores allocated for FY26
- Expected completion by Q3 FY26
Korean Joint Venture - Indichem:
- Groundbreaking ceremony conducted last month
- Commercial production expected to start from H2 FY27
Operational Efficiency:
- Working capital improved to 100 days from 128 days in Q1 FY26
- Strong cash generation from operations: INR 136.50 crores in H1 FY26
Management Commentary
Naresh Patel, Chairman and Managing Director, stated, "Our focus has consistently been on building a long-term sustainable business rather than chasing opportunities. This disciplined approach is now beginning to yield tangible results."
Abhishek Patel, Vice President of Strategy, added, "We are steadily moving towards our vision of becoming a global chemical company with diversified business verticals catering to multiple industries, including pharmaceutical, battery chemicals, semiconductors chemicals, cosmetics, and other specialty chemicals."
Outlook
- The company has revised its EBITDA margin guidance to 28-30% for FY26
- Maintains 25% revenue growth target for FY26
- Expects the electrolyte additives plant to reach optimal capacity utilization in about 3 years
Acutaas Chemicals continues to demonstrate strong growth momentum, driven by its diversified product portfolio and strategic expansions into high-growth segments like battery chemicals and semiconductor chemicals. The company's focus on operational efficiency and margin improvement positions it well for sustained growth in the coming years.
Historical Stock Returns for Ami Organics
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.06% | +2.43% | +16.41% | +53.19% | +118.76% | +260.86% |
15
